ROS1融合基因突变在非小细胞肺癌诊断与治疗中的研究进展

Role of ROS1 fusion gene mutations in diagnosis and treatment of non-small cell lung cancer

摘要: ROS1基因重排/融合在非小细胞肺癌（non-small cell lung cancer，NSCLC）中的发生率约为1%~2%。ROS1基因融合靶向药物的问世，明显改善了ROS1融合晚期NSCLC患者的生存质量和总生存期，但大部分患者在持续用药后仍会出现获得性耐药。本文分别就ROS1融合基因的背景、检测方法、ROS1靶向治疗的临床疗效以及耐药后的策略和展望进行综述。

Abstract: The incidence of ROS1 gene rearrangement/fusion in non-small cell lung cancer (NSCLC) is about 1%-2%. The advent of targeted drugs for ROS1 gene fusion has significantly improved the quality of life and total survival of NSCLC patients with ROS1 fusion; however, acquired drug resistance is still present in most patients after continuous treatment. This review has summarized the background of the ROS1 fusion gene, detection method, clinical efficacy of ROS1-targeted therapy, and strategy and prospect of drug resistance.